Bristol Myers Squibb (NYSE:BMY) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Bristol Myers Squibb Company (NYSE:BMY). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Bristol Myers Squibb stock on November 12th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $53.56 on Thursday. The stock has a market cap of $109.03 billion, a PE ratio of 18.09, a P/E/G ratio of 8.30 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The firm has a 50-day moving average of $47.35 and a 200-day moving average of $47.07. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business’s revenue was up 2.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a $0.63 dividend. The ex-dividend date of this dividend is Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 annualized dividend and a dividend yield of 4.7%. Bristol Myers Squibb’s payout ratio is currently 83.78%.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently made changes to their positions in the company. Keel Point LLC boosted its position in shares of Bristol Myers Squibb by 9.9% during the 3rd quarter. Keel Point LLC now owns 8,054 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 728 shares in the last quarter. Mirabella Financial Services LLP lifted its stake in Bristol Myers Squibb by 158.6% during the third quarter. Mirabella Financial Services LLP now owns 40,545 shares of the biopharmaceutical company’s stock worth $1,825,000 after purchasing an additional 24,867 shares during the last quarter. Farmers National Bank boosted its holdings in shares of Bristol Myers Squibb by 3.9% in the 3rd quarter. Farmers National Bank now owns 10,762 shares of the biopharmaceutical company’s stock valued at $485,000 after purchasing an additional 400 shares in the last quarter. Saranac Partners Ltd bought a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at $288,000. Finally, Swiss Life Asset Management Ltd raised its holdings in shares of Bristol Myers Squibb by 6.4% during the 3rd quarter. Swiss Life Asset Management Ltd now owns 1,142,844 shares of the biopharmaceutical company’s stock worth $51,542,000 after buying an additional 68,565 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BMY has been the topic of a number of research reports. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $52.00 to $61.00 in a report on Monday. Dbs Bank raised shares of Bristol Myers Squibb to a “moderate buy” rating in a report on Thursday, October 2nd. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $37.00 price target (up from $36.00) on shares of Bristol Myers Squibb in a research note on Friday, December 12th. Five analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb presently has a consensus rating of “Hold” and an average price target of $54.62.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.